Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985525 | 0.88 | KMT2A (0.54) | KMT2AMEN1KDM4EHSD17B10GPBAR1 | |
| SCHEMBL2472321 | 0.83 | KMT2A (0.47) | KMT2AMEN1KDM4EHSD17B10GPBAR1 | |
| SCHEMBL2475844 | 0.83 | GPBAR1 (0.59) | KMT2AMEN1KDM4EGPBAR1GAA | |
| SCHEMBL535772 | 0.82 | NPC1 (0.53) | KMT2AMEN1KDM4EHSD17B10GAA | |
| SCHEMBL2471876 | 0.81 | GPBAR1 (0.62) | KMT2AMEN1KDM4EGPBAR1GAA | |
| SCHEMBL1575050 | 0.80 | GPBAR1 (0.66) | KMT2AMEN1KDM4EGPBAR1GAA | |
| SCHEMBL2470754 | 0.80 | RAB9A (0.54) | KMT2AMEN1KDM4EGPBAR1GAA | |
| SCHEMBL3977672 | 0.77 | SMN1; SMN2 (0.50) | KMT2AMEN1KDM4EHSD17B10GAA | |
| SCHEMBL1574735 | 0.76 | KMT2A (0.73) | KMT2AMEN1GPBAR1GAATSHR | |
| SCHEMBL2473629 | 0.75 | KMT2A (0.51) | KMT2AMEN1KDM4EGPBAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | GABRA5, GABRA4, GABRA1 | KMT2A 1742/4885MEN1 4548/4885KDM4E 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.